The Wisconsin Alzheimer’s Institute is committed to health equity and to improving the quality of life of people living with Alzheimer’s disease or other dementia and their families. Through research initiatives, statewide memory clinic development, education and public health programs, we identify and provide strategies to reduce dementia risk and offer access to effective care. We invite you to join us in building a future to remember.
Art Walaszek, MD, public health leader for WAI, was a guest on WPR to discuss the Alzheimer's disease drug aducanumab and its approval by the FDA.
On June 7, the U.S. Food and Drug Administration (FDA) approved the drug aducanumab for the treatment of Alzheimer’s disease.
Thank you MKE Lifestyle for a feature article about WAI Regional Milwaukee Office and their work addressing Alzheimer's disease and dementia in the Milwaukee community.
- More WAI News posts